MannKind (NASDAQ:MNKD) is up 5% after hours in response to its announced program allowing diabetics to purchase inhaled insulin Afrezza (insulin human) direct from the company for as little as $4 per day. Prescriptions will be filled and shipped to patients’ homes by Eagle Pharmacy.
Concurrently, it has launched an enhanced copay and savings card program enabling patients to fill their prescriptions at their local pharmacy for as little as $15.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.